Nakajima, Yasuaki http://orcid.org/0000-0002-2094-5293
Tachimori, Hisateru
Miyawaki, Yutaka
Fujiwara, Naoto
Kawada, Kenro
Sato, Hiroshi
Miyata, Hiroaki
Sakuramoto, Shinichi
Shimada, Hideaki
Watanabe, Masayuki
Kakeji, Yoshihiro
Doki, Yuichiro
Kitagawa, Yuko
Article History
Received: 16 February 2022
Accepted: 11 July 2022
First Online: 28 July 2022
Declarations
:
: The study protocol was approved by the Japan Esophageal Society, the Japanese Society of Gastroenterological Surgery, and the Institutional Review Board of Edogawa Hospital (Approval Number 2020–19).
: Author HM are affiliated of a social collaboration department supported by Grants from National Clinical Database, Johnson & Johnson KK, and Nipro Co. Author YK are supported by grants from Takeda Pharmaceutical Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., DAINIPPON SUMITOMO PHARMA Co., Ltd., EA Pharma Co., Ltd., Astellas Pharma Inc., Toyama Chemical Co., Ltd, MEDICON INC., KAKEN PHARMACEUTICAL CO. LTD., Eisai Co., Ltd., Otsuka Pharmaceutical Factory Inc., TEIJIN PHARMA LIMITED., NIHON PHARMACEUTICAL CO., LTD. and Nippon Covidien Inc.. Author YK also received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Factory Inc., SHIONOGI & CO., LTD., Nippon Covidien Inc., Ethicon, Inc., ONO PHARMACEUTICAL CO., LTD., Olympus Corporation, Bristol-Myers Squibb KK, AstraZeneca KK, MSD KK, Smith & Nephew KK and KAKEN PHARMACEUTICAL CO., LTD.. Other authors declare that they have no conflict of interest.